Literature DB >> 27461127

Integration of QbD risk assessment tools and overall risk management.

Brian Kelley1, Mary Cromwell2, Joe Jerkins2.   

Abstract

Quality by design (QbD) is a global regulatory initiative with the goal of enhancing pharmaceutical development through the proactive design of pharmaceutical manufacturing process and controls to consistently deliver the intended performance of the product. The principles of pharmaceutical development relevant to QbD are described in the ICH guidance documents (ICHQ8-11). An integrated set of risk assessments and related elements developed at Roche/Genentech were designed to provide an overview of product and process knowledge for the production of a recombinant monoclonal antibody. This chapter describes how the risk assessments, logic and interactions of the tools are designed to connect the set of QbD tools and elements into an overarching risk management system. The tools allow comparisons of options based on elective decisions that the sponsor could take and reflect relative values of these options. The overall risk management strategy assures product quality from this enhanced set of assessments and employs a science and risk based approach resulting in a consistent and transparent set of process and product controls and a rational monitoring system.
Copyright © 2016 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Quality by design

Mesh:

Substances:

Year:  2016        PMID: 27461127     DOI: 10.1016/j.biologicals.2016.06.001

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  2 in total

1.  Determination of Critical Quality Attributes for a Biotherapeutic in the QbD Paradigm: GCSF as a Case Study.

Authors:  Sumit K Singh; Deepak Kumar; Anurag S Rathore
Journal:  AAPS J       Date:  2017-09-05       Impact factor: 4.009

2.  Quality by Design risk assessments supporting approved antibody products.

Authors:  Brian Kelley
Journal:  MAbs       Date:  2016-09-12       Impact factor: 5.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.